TSH secreting pituitary tumor — an experience of 20 years follow-up

Thyrotropinoma is a rare pituitary tumor that causes the development of thyrotoxicosis syndrome as a result of hyperproduction of thyroid stimulating hormone (TSH). In the Russian literature over the past 10 years, one case of thyrotropinoma in a child, four cases of TSH-producing pituitary adenoma in women and only one in a man have been described. The article presents a unique clinical case of a 20-years history of observation of a patient with TSH-oma. The rarity of this disease led to the fact that it took more than 10 years to make a correct diagnosis. The first operation of thyroid gland was performed before the diagnosis of pituitary adenoma and inappropriate TSH secretion syndrome. That right hemithyroidectomy was supposed to cure a toxic adenoma of thyroid gland. The diagnosis of thyrotropin-secreting piruitary tumor was established only after 6 years even after finding a combination of pituitary adenoma and thyrotoxicosis. After that, the patient steadfastly refuses neurosurgical treatment, despite the presence of macroadenoma with intrasellar growth. The therapy with somatostatin analogs led to patient’s intolerance with gastrointestinal side effects and hospitalization for acute pancreatitis. The absence of the therapy due to low compliance led to long-term persistence of thyrotoxicosis. The absence of signs and symptoms of expanding tumor mass (visual field defects, loss of vision, headache, partial or total hypopituitarism) demonstrates the slow growth of this kind of pituitary tumor. The long-term effect of elevated TSH levels led to diffuse goiter with compression of the neck organs, and the need of the surgical treatment of the thyroid. Stable euthyroidism after the operation led to stable normoglycemia in the patient with previously diagnosed diabetes mellitus type 2. This fact should keep an attention of physicians and endocrinologists to screen for the secondary reasons of hyperglycemia in a patient with diabetes mellitus manifestation. Long-term history of thyrotoxicosis led to the deleterious effects of thyroid hormone excess on the heart (atrial fibrillation, cardiomyopathy, cardiac failure). Those effects are still observed even after thyroidectomy and medical euthyroidism achievement. This fact demonstrates the importance of early diagnosis and treatment of TSH-omas.

1. Beck-Peccoz P, Brucker-Davis F, Persani L, et al. Thyrotropin-secreting pituitary tumors. Endocr Rev. 1996;17(6):610–638. doi: 10.1210/edrv-17-6-610.

2. Onnestam L, Berinder K, Burman P, et al. National incidence and prevalence of TSH-secreting pituitary adenomas in Sweden. J Clin Endocrinol Metab. 2013;98(2):626−635. doi: 10.1210/jc.2012-3362.

3. Brown RL, Muzzafar T, Wollman R, et al. A pituitary carcinoma secreting TSH and prolactin: a non-secreting adenoma gone awry. Eur J Endocrinol. 2006;154(5):639−643. doi: 10.1530/eje.1.02141.

4. Jailer JW, Holub DA. Remission of Graves’ disease following radiotherapy of a pituitary neoplasm. Am J Med. 1960;28(3):497−500. doi: 10.1016/0002-9343(60)90181-9.

5. Beck-Peccoz P, Lania A, Persani L. TSH-producing adenomas. In: Jameson JL, Degroot LJ, editors. Endocrinology. 7th ed. USA: W.B. Saunders Pub.; 2015. Р. 266−274.

6. Mazerkina NA, Trunin II, Gorelyshev SK, et al. Thyrotropin secreting pituitary adenoma in a child: case report and literature review. Burdenko’s journal of neurosurgery. 2012;76(5):63−69. (In Russ.).

7. Prgijalkovskaja EG, Gasisova DO, Grigoriev AYu, et al. Thyrotropin-producing adenoma: diagnostic challenges (case report). Clinical and experimental thyroidology. 2011;7(2):68−73. (In Russ.). doi: 10.14341/ket20117268-73.

8. Karapetyan AR, Gormolysova EV, Galushko EV. Thyrotropin-producing adenoma. Report of two clinical cases. Clinical and experimental thyroidology. 2016;12(3):37−42. (In Russ.). doi: 10.14341/ket2016337-42.

9. Petrik GG, Kosmacheva ED, Polyakova UI, et al. TSH-secreting pituitary adenoma: late diagnosis and effectiveness of therapy. Problemy endokrinologii. 2017;63(1):39−45. (In Russ.). doi: 10.14341/probl201763139-45.

10. Belyakova NA, Vasyutkova OA, Mukhina YeB, et al. Thyrotropinoma. Lechenie i profilaktika. 2018;8(2):99−101. (In Russ.).

11. Mouslech Z, Somali M, Sakali AK, et al. TSH-secreting pituitary adenomas treated by gamma knife radiosurgery: our case experience and a review of the literature. Hormones (Athens). 2016;15(1):122−128. doi: 10.14310/horm.2002.1640.

12. Ross DS, Burch HB, Cooper DS, et al. American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016;26(10):1343−1421. doi: 10.1089/thy.2016.0229.

13. Beck-Peccoz P, Persani L, Mannavola D, et al. Pituitary tumours: TSH-secreting adenomas. Best Pract Res Clin Endocrinol Metab. 2009;23(5):597−606. doi: 10.1016/j.beem.2009.05.006.

14. Beck-Peccoz P, Lania A, Beckers A, et al. 2013 European Thyroid Association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors. Eur Thyroid J. 2013;2(2):76−82. doi: 10.1159/000351007.

15. Corbetta S, Pizzocaro A, Peracchi M, et al. Multiple endocrine neoplasia type 1 in patients with recognized pituitary tumours of different types. Clin Endocrinol (Oxf). 1997;47(5):507−512. doi: 10.1046/j.1365-2265.1997.3311122.x.

16. Socin HV, Chanson P, Delemer B, et al: The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. Eur J Endocrinol. 2003;148(4):433–442. doi: 10.1530/eje.0.1480433.

17. Daly AF, Tichomirowa MA, Petrossians P, et al. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab. 2010;95(11):373−383. doi: 10.1210/jc.2009-2556.

18. Fadeev VV. Review of European Thyroid Association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumours. Clinical and experimental thyroidology. 2016;12(4):4−10. (In Russ.). doi: 10.14341/ket20164.

19. Shestakova TP, Komerdus IV. Diagnostika redkikh zabolevanii shchitovidnoi zhelezy. Russkii meditsinskii zhurnal. 2015;23(8):458−460. (In Russ.).

20. Kaldymova VA, Kiyaev AV, Tyulpakov AN. Syndromes of resistance to thyroid hormone. Clinical and experimental thyroidology. 2013;9(1):51−53. (In Russ.). doi: 10.14341/ket20139151-53.

21. Beck-Peccoz P, Persani L, Faglia G. Glycoprotein hormone α-subunit in pituitary adenomas. Trends Endocrinol Metab. 1992;3(2):41–45. doi: 10.1016/1043-2760(92)90041-x.

22. Nazato DM, Abucham J. Diagnosis and treatment of TSH-secreting adenomas: review of a longtime experience in a reference center. J Endocrinol Invest. 2018;41(4):447−454. doi: 10.1007/s40618-017-0770-3.

23. Malchiodi E, Profka E, Ferrante E, et al. Thyrotropin-secreting pituitary adenomas: outcome of pituitary surgery and irradiation. J Clin Endocrinol Metab. 2014;99(6):2069–2076. doi: 10.1210/jc.2013-4376.

24. Socin HV, Beck-Peccoz P, Brucker-Davis F, et al. Thyrotropin-secreting pituitary tumors. Endocr Rev. 1996;17(6):610–638. doi: 10.1210/edrv-17-6-610.

25. Wallace IR, Healy E, Cooke RS, et al. TSH-secreting pituitary adenoma: benefits of pre-operative octreotide. Endocrinol Diabetes Metab Case Rep. 2015;2015:150007. doi: 10.1530/EDM-15-0007.

26. Rimareix F, Grunenwald S, Vezzosi D, et al. Primary medical treatment of thyrotropin-secreting pituitary adenomas by first generation somatostatin analogs: a case study of seven patients. Thyroid. 2015;25(8):877–882. doi: 10.1089/thy.2015.0041.

27. Fukuhara N, Horiguchi K, Nishioka H, et al. Short-term preoperative octreotide treatment for TSH-secreting pituitary adenoma. Endocr J. 2015;62(1):21−27. doi: 10.1507/endocrj.EJ14-0118.